Skip to main content

Advertisement

Table 2 Effect of rituximab treatment in patients with rheumatoid arthritis

From: Suppressed diversity of survivin splicing in active rheumatoid arthritis

  Before RTX After RTXa
DAS28 score 5.89 ± 0.6 4.34 ± 0.7
Rheumatoid factor (IU/ml)   
 IgG 41.5 ± 29.3 22.7 ± 19.5*
 IgM 67.2 ± 31.1 50.2 ± 38.3
 IgA 41.0 ± 38.3 25.0 ± 19.5
WBC count (×109/l)   
 PBMCs 6.5 ± 3.1 7.8 ± 3.2
 BM 2.1 ± 1.4 2.6 ± 1.6
CD19+ (%)b   
 PBMCs 7.7 ± 3.8 0
 BM 9.4 ± 4.3 1.3 ± 1.2
CD3+ (%)b   
 PBMCs 45.9 ± 15.8 42.5 ± 12.9
 BM 28.0 ± 9.8 29.4 ± 16.5
  1. Values presented as mean ± standard deviation, n = 23
  2. a Samples 1–3 months after RTX treatment
  3. b From the lymphocyte population
  4. * p = 0.008
  5. p <0.0001
  6. BM bone marrow, DAS28 Disease Activity Score based on evaluation of 28 joints, PBMC peripheral blood mononuclear cells, RTX rituximab, WBC white blood cell